Chapter 5 180 For identification of patients with resistant outcomes (resistant vs not resistant (i.e., sensitive and intermediate)), concordance was 91% and for identification of patients with sensitive outcomes (sensitive vs not sensitive (i.e., resistant and intermediate)), concordance was 93%. Table 1. Patient characteristics and outcomes for all cohorts: development, validation set 1, validation set 2, and chemotherapy cohort. Development (n = 116) Validation 1 (n = 98) Validation 2 (n = 75) Chemotherapy (n = 68) Age median (range) 65 (43-83) 64 (29-77) 65 (35-78) 64 (39-77) Gender, n (%) Male 66 (57) 51 (52) 48 (64) 52 (76) Female 50 (43) 47 (48) 27 (36) 16 (24) PS, n (%) 0 36 (32) 20 (20) 18 (32) 35 (51) 1 60 (54) 65 (66) 37 (66) 29 (43) 2+ 15 (14) 13 (13) 1 (2) 4 (6) Smoking status, n (%) Ever 104 (91) 88 (92) 61 (92) 64 (94) Never 10 (9) 8 (8) 5 (8) 4 (6) Histology, n (%) Adeno 77 (66) 42 (74) 49 (65) 47 (75) Squamous 26 (22) 10 (18) 17 (23) 12 (19) Other 13 (11) 5 (9) 9 (12) 4 (6) PD-L1, n (%) ≥1% 33 (28) 12 (14) 16(21) 0 (0) <1% 43 (37) 30 (29) 9 (12) 0 (0) NA 40 (34) 56 (57) 50 (67) 68 (100) Response, n (%) CR 1 (1) 1 (0) 0 (0) 0 (0) PR 16 (14) 28 (28) 15 (20) 7 (10) SD 19 (16) 26 (33) 25 (33) 23 (34) PD 65 (56) 37 (33) 31 (41) 22 (32) NA/NE 15 (13) 6 (7) 4 (5) 16 (24) PFS (months) Median 2.6 4.1 4.3 3.5 OS (months) Median 8.5 8.4 12.0 8.0 Abbreviations: %, % of patients with available data; adeno, adenocarcinoma; NA, not available; NE, not evaluable; PD, progressive disease; PD-L1, PD-L1 expression; PS, performance status; SD, stable disease.
RkJQdWJsaXNoZXIy MTk4NDMw